Valeant Pharmaceuticals Intl Inc  

(Public, TSE:VRX)   Watch this stock  
Find more results for TSE:BVF
21.02
-0.17 (-0.80%)
Feb 17 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 20.70 - 21.16
52 week 17.19 - 131.70
Open 21.00
Vol / Avg. 955,119.00/1.25M
Mkt cap 6.90B
P/E     -
Div/yield     -
EPS -8.48
Shares 341.19M
Beta -0.64
Inst. own 83%
Mar 13, 2017
Q4 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jan 10, 2017
Valeant Pharmaceuticals International Inc at JPMorgan Healthcare Conference
Dec 14, 2016
Valeant Pharmaceuticals International Inc at BMO Capital Markets Prescriptions for Success Healthcare Conference - Webcast
Dec 13, 2016
Valeant Pharmaceuticals International Inc at Guggenheim Boston Healthcare Conference
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -49.17% -2.75%
Operating margin -34.80% 14.43%
EBITD margin - 45.71%
Return on average assets -10.47% -0.76%
Return on average equity -103.28% -5.21%
Employees 22,000 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 60
Paul S. Herendeen Chief Financial Officer, Executive Vice President - Finance
Age: 60
Pavel Mirovsky President, General Manager, Europe
Age: 65
Christina Ackermann Executive Vice President, General Counsel
Thomas Appio Executive Vice President, President - Asia Pacific
Louis W. Yu Ph.D. Chief Quality Officer, Global Quality
Age: 65
Thomas W. Ross Sr. Lead Independent Director
Age: 65
William A. Ackman Independent Director
Age: 49
Richard U. DeSchutter Independent Director
Fredric N. Eshelman Independent Director
Age: 67